Market research
BCYC Bicycle Therapeutics Ltd
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 306M
- P/E ratio
- Not available
- Analyst target
- 9.5
- Dividend yield
- Not available
- Beta
- 1.53
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US0887861088
- Market cap
- 306M
- P/E ratio
- Not available
- Analyst target
- 9.5
- Dividend yield
- Not available
- Beta
- 1.53
About
About Bicycle Therapeutics Ltd
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the BCYC discussion.
5 years, 4 months ago
Bicycle Therapeutics plc is currently in a long term uptrend where the price is trading 23.3% above its 200 day moving average.
From a valuation standpoint, the stock is 95.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 56.2.
Bicycle Therapeutics plc's total revenue sank by 27.1% to $4M since the same quarter in the previous year.
Its net income has dropped by 295.7% to $-17M since the same quarter in the previous year.
Finally, its free cash flow fell by 222.1% to $-17M since the same quarter in the previous year.
Based on the above factors, Bicycle Therapeutics plc gets an overall score of 2/5.